Grape ingredient resveratrol increases beneficial fat hormone

Posted: Thursday, January 06, 2011

Print contact: Will Sansom, (210) 567-2579
Broadcast contact: Lucie Portela, (210) 567-2570


Feng Liu, Ph.D., professor of pharmacology and member, Barshop Institute at the UT Health Science Center San Antonioclear graphic
Feng Liu, Ph.D., professor of pharmacology and member, Barshop Institute at the UT Health Science Center San Antonio 

Email Printer Friendly Format
 

SAN ANTONIO (Jan. 7, 2011) — Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

Resveratrol stimulates the expression of adiponectin, a hormone derived from cells that manufacture and store fat, the team found. Adiponectin has a wide range of beneficial effects on obesity-related medical complications, said senior author Feng Liu, Ph.D., professor of pharmacology and member of the Barshop Institute of Longevity and Aging Studies at the Health Science Center.

Both adiponectin and resveratrol display anti-obesity, anti-insulin resistance and anti-aging properties.

“Results from these studies should be of interest to those who are obese, diabetic and growing older,” Dr. Liu said. “The findings should also provide important information on the development of novel therapeutic drugs for the treatment of these diseases.”

The researchers confirmed the finding in cells and animal models. The study is in the Jan. 7 issue of the Journal of Biological Chemistry.

Previous studies

In July 2009 in the journal Nature, the Barshop Institute and collaborators reported that the compound rapamycin extended life in mice. Rapamycin, like resveratrol, is under scrutiny for its beneficial health effects.

Grapes (image courtesy of USDA)clear graphic
Grapes (image courtesy of USDA) 

 

In 2010, Dr. Liu and colleagues announced that resveratrol inhibits activity of the mammalian target of rapamycin (mTOR). This discovery was included in the prestigious Faculty of 1000 (F1000), a service that identifies and evaluates the most important articles in biology and medical research publications. The selection process involves a peer-nominated global “faculty” of the world's leading scientists and clinicians who rate the best of the articles they read and explain their importance.

A reviewer said the study, which appeared in the Journal of Biological Chemistry, would open up work in a new area: explaining how resveratrol and rapamycin synergistically achieve their results.

# # #


The University of Texas Health Science Center at San Antonio, one of the country’s leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving National Institutes of Health (NIH) funding. Research and other sponsored program activity totaled a record $259 million in fiscal year 2009. The university’s schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 26,000 graduates. The $744 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.



HOME [HSC NEWS] | About UTHSCSA | News Releases | Mission Magazine | Grand Rounds Newly Granted | Submit News | HSC News Archive | Video Index
Photo Archive Library News | Update(Student Newsletter) | RAHC